Type 1 Diabetes

What it is

Type 1 diabetes is an autoimmune disease in which the pancreas makes little or no insulin, and about 5% to 10% of diabetes cases are type 1. In this condition, the immune system attacks and destroys the insulin-producing beta cells in the pancreas, leading to absolute insulin deficiency. Because insulin is required for glucose to move from the bloodstream into cells, people with type 1 diabetes need lifelong insulin treatment. Without insulin, blood glucose rises and can progress to diabetic ketoacidosis (DKA), a medical emergency.

Type 1 diabetes often begins in childhood, adolescence, or young adulthood, but it can occur at any age. Older names include insulin-dependent diabetes and juvenile diabetes, though both are incomplete because some adults also develop it. Type 1 diabetes is different from type 2 diabetes, which is more strongly linked to insulin resistance and is much more common overall.

Common symptoms at onset include:

1. Frequent urination
2. Excessive thirst
3. Unexplained weight loss
4. Increased hunger
5. Fatigue
6. Blurred vision

Symptoms may appear over days to weeks. In some people, the first presentation is DKA, with vomiting, abdominal pain, deep breathing, dehydration, and confusion.

How it works

In type 1 diabetes, immune-mediated injury gradually or rapidly destroys pancreatic beta cells. As beta-cell mass falls, the body can no longer make enough insulin to control blood glucose. Insulin normally helps glucose enter muscle and fat cells and suppresses excess glucose production by the liver. When insulin is absent, blood glucose rises, fat breakdown increases, and the liver produces ketones.

This process explains two major acute problems:

Problem	Why it happens
Hyperglycemia	Glucose cannot enter cells effectively and accumulates in blood
Diabetic ketoacidosis	Lack of insulin drives ketone production and metabolic acidosis

Type 1 diabetes is usually associated with autoimmune markers such as antibodies to GAD65, IA-2, insulin, or ZnT8. Genetic susceptibility matters, especially certain HLA types, but genes alone do not fully explain who develops the disease. Environmental triggers are still being studied.

The rate of beta-cell loss varies. Some people, especially adults, have a slower onset and may initially be misclassified as having type 2 diabetes. A short "honeymoon phase" can occur soon after diagnosis, when remaining beta cells still make some insulin and insulin needs temporarily fall.

Diagnosis / how it's measured

Type 1 diabetes is diagnosed using standard diabetes criteria plus clinical context and, when needed, tests that support autoimmune beta-cell failure. Diabetes can be diagnosed by elevated fasting plasma glucose, a high 2-hour glucose during an oral glucose tolerance test, an elevated HbA1c, or a random plasma glucose in a person with classic symptoms.

Tests that help distinguish type 1 from type 2 diabetes include:

Test	What it may show
Islet autoantibodies	Supports autoimmune type 1 diabetes
C-peptide	Low levels suggest reduced endogenous insulin production
Blood or urine ketones	Helps detect ketosis or DKA
HbA1c	Reflects average glucose over about 3 months

Clinicians also assess for complications and associated autoimmune disease. People with type 1 diabetes have higher rates of autoimmune thyroid disease and celiac disease than the general population, so screening is often considered.

For day-to-day management, glucose is measured with finger-stick blood glucose testing, continuous glucose monitoring (CGM), or both. Many people also use ketone testing during illness, persistent hyperglycemia, or symptoms of DKA.

In India, diagnosis and ongoing care may involve endocrinologists, pediatricians, or general physicians depending on access. Access to insulin, glucose strips, CGM, and diabetes education can vary widely by region and cost.

Evidence and uses

There is currently no cure for established type 1 diabetes, but it can be treated effectively. The foundation of care is insulin replacement, along with glucose monitoring, nutrition planning, physical activity, and diabetes self-management education.

Main treatment components include:

1. Insulin therapy: given by multiple daily injections or an insulin pump
2. Glucose monitoring: self-monitoring of blood glucose and/or CGM
3. Education: carbohydrate counting, hypoglycemia treatment, sick-day rules, ketone testing
4. Lifestyle support: regular meals, exercise planning, sleep, and follow-up care

Evidence supports intensive glucose management to reduce the risk of long-term complications affecting the eyes, kidneys, nerves, heart, and blood vessels. Diabetes technology has improved care, especially CGM and automated insulin delivery systems, which can increase time in range and reduce hypoglycemia in many patients.

A newer development is teplizumab, an anti-CD3 monoclonal antibody approved in the United States to delay progression from stage 2 to stage 3 type 1 diabetes in selected high-risk individuals. This does not reverse established type 1 diabetes, and access is limited.

Nutrition matters, but no single diet cures type 1 diabetes. Meal planning is usually matched to insulin dosing. In India, this often means adjusting insulin around common eating patterns such as rice- or roti-based meals, mixed dishes, festival foods, and variable meal timing. Medical nutrition therapy should be individualized rather than based on blanket food bans.

When to see a clinician

See a clinician promptly if symptoms suggest new diabetes, especially excessive thirst, frequent urination, weight loss, or fatigue. Children and adults with possible type 1 diabetes should not wait for symptoms to "settle" because DKA can develop quickly.

Seek urgent or emergency care for signs of DKA, including:

• Vomiting
• Abdominal pain
• Rapid or deep breathing
• Fruity-smelling breath
• Drowsiness or confusion
• Very high glucose with positive ketones

People already diagnosed with type 1 diabetes should contact their care team if they have repeated hypoglycemia, persistent high glucose, ketones during illness, trouble affording insulin or supplies, or uncertainty about dose adjustments. Pregnancy, surgery, severe infection, and steroid treatment also need closer medical supervision.

Limitations and open questions

Type 1 diabetes is well defined clinically, but several areas remain uncertain. Researchers are still studying which environmental exposures trigger autoimmunity, why onset timing differs so much between people, and how to preserve beta-cell function after diagnosis.

Screening with islet autoantibodies can identify people at high risk before symptoms start, especially relatives of affected individuals, but the best way to implement broad screening is still being worked out. Evidence is stronger for identifying risk than for preventing disease in the general population.

Technology has improved outcomes, but access remains uneven. Insulin pumps, CGM, and hybrid closed-loop systems are not available or affordable for everyone, including many patients in low- and middle-income settings.

Finally, type 1 diabetes is not caused by eating sugar, lack of exercise, or poor parenting. It is an autoimmune disease. Even with excellent care, glucose levels can vary because of illness, hormones, stress, exercise, and day-to-day changes in insulin absorption.